BALA CYNWYD, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Regulus Therapeutics Inc. (Nasdaq – RGLS)
Under the terms of the Merger Agreement, Regulus will be acquired by Novartis AG (“Novartis”) for an initial payment of $7.00 per share in cash at closing, or $0.8 billion. In addition, Regulus shareholders will receive a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus’ lead product candidate, farabursen. The investigation concerns whether the Regulus Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.
Additional information can be found at https://www.brodskysmith.com/cases/regulus-therapeutics-inc-nasdaq-rgls/.
Kronos Bio, Inc. (Nasdaq - KRON)
Under the terms of the agreement, Kronos will be acquired by Concentra Biosciences, LLC ( “Concentra”) for $0.57 in cash per share of Kronos Bio common stock, plus one non-tradeable contingent value right (“CVR”). The investigation concerns whether the Kronos Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.
Additional information can be found at https://www.brodskysmith.com/cases/kronos-bio-inc-nasdaq-kron/.
Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP)
Under the terms of the agreement, Coeptis will be acquired by Z Squared Inc. (“Z Squared”). Holders of the outstanding Z Squared shares will receive equity in Coeptis in exchange for 9,000 U.S. based dogecoin mining machines at closing. The investigation concerns whether the Coeptis Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.
Additional information can be found at https://www.brodskysmith.com/cases/coeptis-therapeutics-holdings-inc-nasdaq-coep/.
Pacific Premier Bancorp, Inc. (Nasdaq - PPBI)
Under the terms of the agreement, Pacific Premier will be acquired by Columbia Banking System, Inc. (“Columbia”) (Nasdaq - COLB). Pacific Premier stockholders will receive 0.9150 of a share of Columbia common stock for each Pacific Premier share they own. The merger is valued at approximately $2.0 billion, or $20.83 per Pacific Premier share, based on Columbia’s closing stock price of $22.77 on April 22, 2025. Following closing, Pacific Premier stockholders will own approximately 30% of Columbia's outstanding shares of common stock. The investigation concerns whether the Pacific Premier Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares. For example, the deal consideration is below the 52-week high of $30.28 for the Company’s shares.
Additional information can be found at https://www.brodskysmith.com/cases/pacific-premier-bancorp-inc-nasdaq-ppbi/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
